COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
NIH staff guidance on coronavirus (NIH Only): https://employees.nih.gov/pages/coronavirus/
9th Matilda White Riley Honors: 2016
Distinguished Lecturer: Caryn Lerman Ph.D.
John H. Glick, M.D. Professor In Cancer Research, Department of Psychiatry
University of Pennsylvania
Presentation: Bridging Behavioral and Cognitive Neuroscience Research to Advance the Treatment of Tobacco Dependence
Dr. Caryn Lerman is the Vice Dean for Strategic Initiatives for Penn Medicine and the John H. Glick Professor for Cancer Research in the Department of Psychiatry. Formerly, she served as the Co-Director of the Penn Medicine Translational Neuroscience Center, Deputy Director of the Abramson Cancer Center, and Interim Chair of the Department of Psychiatry. Dr. Lerman received her doctorate in Clinical Psychology from the University of Southern California, and has particular expertise in strategic planning as well as leadership coaching.
Dr. Lerman is nationally recognized for her research in the areas of cancer prevention, nicotine addiction, and pharmacogenetics. Her work is distinguished not only by its interdisciplinary bridging, but also by its relevance to clinical practice and health policy. Her landmark contributions to cancer prevention include the first empirical data on decision-making and outcomes of genetic testing for cancer susceptibility. This work led to an interest in the genetic underpinnings of cancer risk behaviors, leading to her pioneering work identifying genetic variants related to tobacco use and smoking cessation treatment response. These studies culminated in the first prospective stratified pharmacogenetic trial in the field of tobacco dependence, with a considerable impact on the application of precision medicine for tobacco dependence treatment.
Dr. Lerman has also created a highly novel research program that harnesses advances in cognitive neuroscience to promote cancer risk behavior change, laying the foundation for her receipt of a coveted National Cancer Institute Outstanding Investigator Award. Her innovative scientific program is likely to have transformative effects on current paradigms for behavioral cancer prevention.
Dr. Lerman’s research is represented in more than 365 peer-reviewed publications, congressional testimonies and government reports, including a Surgeon General’s Report. Her publications have been cited more than 20,000 times, and she has been continuously funded by the NIH since 1990 as principal investigator of $75 million in grants. Her honors include the APA Award for Outstanding Contributions to Health Psychology, the ASPO Cullen Award for Tobacco Research, and the Ochsner Award for Research Relating Smoking and Health. She is past President of the Society for Research on Nicotine and Tobacco, and has served on the National Institute on Drug Abuse Advisory Council, the National Cancer Institute Board of Scientific Advisors, and the National Advisory Council for Human Genome Research. She is an elected member of the National Academy of Medicine.
9th Matilda White Early Stage Investigator Paper Awardees
Stephanie H. Cook, Dr.P.H.. M.P.H.
Postdoctoral Research Fellow
New York University
Transitions in friendship attachment during adolescence are associated with developmental trajectories of depression through adulthood
Christopher S. Marcum, Ph.D.
National Human Genome Research Institute
Inter-generational contact from a network perspective
Ian M. McDonough, Ph.D.
The University of Alabama
The Synapse Project: Engagement in mentally challenging activities enhances neural efficiency
Sara Moorman, Ph.D.
Mechanisms Linking Neighborhood Age Composition to Health